These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 21893538)

  • 1. Progress in the rational design of an AIDS vaccine.
    Nabel GJ; Kwong PD; Mascola JR
    Philos Trans R Soc Lond B Biol Sci; 2011 Oct; 366(1579):2759-65. PubMed ID: 21893538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.
    Haynes BF; Montefiori DC
    Expert Rev Vaccines; 2006 Jun; 5(3):347-63. PubMed ID: 16827619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
    Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
    J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based vaccine design in HIV: blind men and the elephant?
    Pejchal R; Wilson IA
    Curr Pharm Des; 2010; 16(33):3744-53. PubMed ID: 21128885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV. The modern era of HIV-1 vaccine development.
    Mascola JR
    Science; 2015 Jul; 349(6244):139-40. PubMed ID: 26160931
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
    Chakrabarti BK; Pancera M; Phogat S; O'Dell S; McKee K; Guenaga J; Robinson J; Mascola J; Wyatt RT
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):877-87. PubMed ID: 21158699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Features of Broadly Neutralizing Antibodies and Rational Design of Vaccine.
    Zhou T; Xu K
    Adv Exp Med Biol; 2018; 1075():73-95. PubMed ID: 30030790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
    Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
    Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fusion proteins of HIV-1 envelope glycoprotein gp120 with CD4-induced antibodies showed enhanced binding to CD4 and CD4 binding site antibodies.
    Chen W; Feng Y; Wang Y; Zhu Z; Dimitrov DS
    Biochem Biophys Res Commun; 2012 Sep; 425(4):931-7. PubMed ID: 22906742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AIDS/HIV. A boost for HIV vaccine design.
    Burton DR; Weiss RA
    Science; 2010 Aug; 329(5993):770-3. PubMed ID: 20705840
    [No Abstract]   [Full Text] [Related]  

  • 13. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 neutralization: mechanisms and relevance to vaccine design.
    Zwick MB; Burton DR
    Curr HIV Res; 2007 Nov; 5(6):608-24. PubMed ID: 18045117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent strategies targeting HIV glycans in vaccine design.
    Horiya S; MacPherson IS; Krauss IJ
    Nat Chem Biol; 2014 Dec; 10(12):990-9. PubMed ID: 25393493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioorganic approaches towards HIV vaccine design.
    Wang LX
    Curr Pharm Des; 2003; 9(22):1771-87. PubMed ID: 12871196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein.
    Chen J; Kovacs JM; Peng H; Rits-Volloch S; Lu J; Park D; Zablowsky E; Seaman MS; Chen B
    Science; 2015 Jul; 349(6244):191-5. PubMed ID: 26113642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.
    Wu X; Yang ZY; Li Y; Hogerkorp CM; Schief WR; Seaman MS; Zhou T; Schmidt SD; Wu L; Xu L; Longo NS; McKee K; O'Dell S; Louder MK; Wycuff DL; Feng Y; Nason M; Doria-Rose N; Connors M; Kwong PD; Roederer M; Wyatt RT; Nabel GJ; Mascola JR
    Science; 2010 Aug; 329(5993):856-61. PubMed ID: 20616233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost.
    Joachim A; Ahmed MIM; Pollakis G; Rogers L; Hoffmann VS; Munseri P; Aboud S; Lyamuya EF; Bakari M; Robb ML; Wahren B; Sandstrom E; Nilsson C; Biberfeld G; Geldmacher C; Held K
    Front Immunol; 2020; 11():719. PubMed ID: 32411138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.